CompletedNot Applicable

: Identification of Non-alcoholic Steato-hepatitis Cases in a Sample of Type 2 Diabetes Patients, with a Disruption of the Liver Function Tests, At the Pointe-à-Pitre University Hospital

Guadeloupe103 participantsStarted 2018-06-21

Plain-language summary

Non-alcoholic steatohepatitis (NASH) develops on insulin resistance, especially in patients with carbohydrate tolerance. NASH may progress to more extensive fibrosis, including cirrhosis, but also to HCC with or without cirrhosis in 10 to 20% of cases. The main objective of our research is to identify the prevalence of NASH in a sample of 100 patients with type 2 diabetes mellitus (T2DM), consulting in the PAP hospital and having a liver function disorder

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Type 2 diabetes mellitus patient with impaired hepatic function (transaminases and / or PAL and / or gamma-GT\> Norm) * Age ≥18 years * Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research). * Affiliate or beneficiary of a social security scheme. Exclusion Criteria: * Pregnancy or breast-feeding * No diabetes or type 1 diabetes * Chronic hepatopathy of other origin: viral B, C, alcohol, hemochromatosis, α1-antitrypsin deficiency, Wilson's disease, autoimmune hepatitis

What they're measuring

fibrotest-Actitest

Timeframe: 24 hours

NASH test

Timeframe: 24 hours

NAFDL fibrosis score

Timeframe: 24 hours

Trial details

NCT IDNCT06738810

SponsorCentre Hospitalier Universitaire de la Guadeloupe

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-02-01

View on ClinicalTrials.gov More Non-alcoholic Steato-hepatitis trials